Results 141 to 150 of about 49,135 (301)

The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit–risk ratio

Therapeutic Advances in Neurological Disorders, 2015
Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of
Apostolos Safouris, Nikos Triantafyllou, John Parissis, Georgios Tsivgoulis   +3 more
doaj   +1 more source

UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.

PLoS ONE, 2015
IntroductionThe fast, precise, and accurate measurement of the new generation of oral anticoagulants such as dabigatran and rivaroxaban in patients' plasma my provide important information in different clinical circumstances such as in the case of ...
Joachim Kuhn, Tatjana Gripp, Tobias Flieder, Marcus Dittrich, Doris Hendig, Jessica Busse, Cornelius Knabbe, Ingvild Birschmann   +7 more
doaj   +1 more source

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation -a look beyond the excellent results [PDF]

, 2012
In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the setting of stroke prevention in atrial fibrillation.
Crippa, L, Falanga, A, Finazzi, G, Manotti, C., Marongiu, F, Moia, M, Palareti, G, Pengo, V, Poli, D, Policarpo, D, SIRAGUSA, Sergio, TESTA, Silvia, Tiraferri, E, Tosetto, A, Tripodi, A   +14 more
core   +1 more source

Anticoagulation management for cardiopulmonary bypass using TEG® 6 s in a patient receiving both heparin and dabigatran

JA Clinical Reports
Background It is difficult to evaluate adequate dose of heparin for cardiopulmonary bypass (CPB) by activated clotting time (ACT) in a patient receiving both heparin and dabigatran because dabigatran can also prolong ACT.
Yu Kawada, Nobuyuki Katori, Keiko Kaji, Shoko Fujioka, Tomoki Yamaguchi   +4 more
doaj   +1 more source

Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation: An Evidence Based Case Report

Majalah Kardiologi Indonesia, 2013
Background. Atrial fibrillation (AF) increases the risk of having stroke as high as five fold. Anticoagulant administration such as vitamin K antagonist has been used regularly to reduce the occurence of stroke.
Alvin Nursalim, Yoga Yuniadi
doaj   +1 more source

P4819Rapid determination of the anticoagulant effects of dabigatran in whole blood using ROTEM and a thrombin-based trigger [PDF]

, 2018
Viktor Taune, Mika Skeppholm, Anna Ågren, Gunilla Gryfelt, Rickard E. Malmström, Agneta Wikman, Håkan Wallén   +6 more
openalex   +1 more source

Dabigatran-based dual antithrombotic therapy for patients with atrial fibrillation and ST-elevation myocardial infarction undergoing percutaneous coronary intervention

, 2021
Dominick J. Angiolillo, Mattía Galli
openalex   +2 more sources

Dabigatran etexilate [PDF]

British Journal of Clinical Pharmacology, 2010
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

Dabigatran Etexilate [PDF]

, 2011
Graeme J. Hankey, John W. Eikelboom
openalex   +1 more source

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies [PDF]

, 2017
Stephen H. Norris, Steven Ramael, Ippei Ikushima, Wouter Haazen, Akiko Harada, Viktoria Moschetti, Susumu Imazu, Paul Reilly, Benjamin Lang, Joachim Stangier, Stephan Glund   +10 more
openalex   +1 more source